1.
Artigo
| IMSEAR
| ID: sea-223068
2.
3.
Indian J Dermatol Venereol Leprol
;
2019 Mar; 85(2): 226-228
Artigo
| IMSEAR
| ID: sea-192463
4.
Indian J Dermatol Venereol Leprol
;
2016 Nov-Dec; 82(6): 708-711
Artigo
em Inglês
| IMSEAR
| ID: sea-178517
5.
An. bras. dermatol
;
91(5): 700-701, Sept.-Oct. 2016. graf
Artigo
em Inglês
| LILACS
| ID: biblio-827742
6.
An. bras. dermatol
;
91(5): 642-644, Sept.-Oct. 2016. graf
Artigo
em Inglês
| LILACS
| ID: biblio-827761
RESUMO
Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Assuntos
Humanos , Masculino , Idoso , Neoplasias Cutâneas/tratamento farmacológico , Síndrome de Sézary/tratamento farmacológico , Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos/uso terapêutico , Neoplasias Cutâneas/sangue , Contagem de Células Sanguíneas , Antígenos de Diferenciação de Linfócitos T/metabolismo , Síndrome de Sézary/sangue , Resultado do Tratamento , Alemtuzumab
7.
Indian J Dermatol Venereol Leprol
;
2016 May-June; 82(3): 356-357
Artigo
em Inglês
| IMSEAR
| ID: sea-178222
8.
Indian J Dermatol Venereol Leprol
;
2014 Nov-Dec; 80(6): 542-544
Artigo
em Inglês
| IMSEAR
| ID: sea-154900